| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Real-world-evidence, prospective-observational study to evaluate safety and effectiveness of rabeprazole dual-delayed-release capsules in patients with gastroesophageal reflux disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Parimal Lawate, Virender Chauhan, L Rajendra Prasad, Abhimanrao Pawar, Atul G Puranik, Alok Bansal, Abhiram Koganti, Ashok Jaiswal, Pranali Puradkar and Kunal Jhaveri |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Kunal Jhaveri, MD, Department of Medical Affairs, Zydus Healthcare Limited, Zydus Tower, CTS 460/6, Village Pahadi Off IB Patel Road, Goregaon East, Mumbai 400063, Mahārāshtra, India. kunal.jhaveri@zyduslife.com |
| Key Words |
Gastroesophageal reflux disease; Heartburn; Acid reflux; Rabeprazole; Dual delayed-release |
| Core Tip |
The novel dual delayed-release formulation of rabeprazole, Happi ER, addresses the unmet needs of gastroesophageal reflux disease (GERD) management by offering both immediate and sustained acid suppression. This real-world evidence study demonstrated significant improvements in heartburn severity, reduced night-time awakenings, and enhanced patient satisfaction, particularly in patients with mild-to-moderate GERD. With a safety profile comparable to that of traditional proton pump inhibitors and superior efficacy in managing nocturnal symptoms, Happi ER provides a comprehensive and reliable solution for long-term GERD management. |
| Publish Date |
2025-03-03 07:31 |
| Citation |
<p>Lawate P, Chauhan V, Prasad LR, Pawar A, Puranik AG, Bansal A, Koganti A, Jaiswal A, Puradkar P, Jhaveri K. Real-world-evidence, prospective-observational study to evaluate safety and effectiveness of rabeprazole dual-delayed-release capsules in patients with gastroesophageal reflux disease. <i>World J Gastrointest Pharmacol Ther</i> 2025; 16(1): 103898</p> |
| URL |
https://www.wjgnet.com/2150-5349/full/v16/i1/103898.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v16.i1.103898 |
